RxDoctor Payments Data

John Knoedler, MD

Urology · Hershey, PANPI 1578794459

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,550 of the $5,276 with a category attached, or 86.2%. Boston Scientific accounts for 94.7% of it on its own, with 3 other manufacturers making up the rest.

$5,276in general payments, 2019–2025

Across 9 payments — averaging $586.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$5K
  • Richard Wolf Medical Instruments Corp.$146
  • Photocure Inc$92
  • Astellas Pharma US Inc$42
$53,600in research payments, 2019–2025

Across 10 payments — averaging $5359.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$53K
  • Urogen Pharma, Inc.$352

What the payments were for

  • Consulting fees$4,55086%
  • Travel & lodging$2525%
  • Food & beverage$4749%

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,276 in reported general payments places this provider in the 70th percentile of 596 urology providers in Pennsylvania.

See all urology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$14,485
Medicare patients
44
Services billed
95

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Potassium Citrate ErPotassium Citrate43$7,396
Finasteride73$546
Tamsulosin Hcl49$526
Oxybutynin Chloride ErOxybutynin Chloride16$348

Paid to pharmacies, not to this prescriber.

Other urology in Hershey

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →